|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chromogranin A (CgA), which is a major protein in adrenal chromaffin cells and adrenergic neurons, is a clinically relevant endocrine and neuroendocrine tumor marker including pheochromocytomas, neuroblastomas, and related neurogenic tumors.
|
31682468 |
2020 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma.
|
31027285 |
2019 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Positive chromogranin A staining of the tumor cells confirmed a diagnosis of pheochromocytoma.
|
30078826 |
2018 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the immunostaining of CgA in the tumor cells showed peculiar dot-like staining located corresponding to Golgi complex in the perinuclear area, rather than the diffuse cytoplasmic staining usually observed in epinephrine- or norepinephrine-producing functional pheochromocytomas and paragangliomas.
|
27743246 |
2017 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma.
|
28948824 |
2017 |
|
Pheochromocytoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A retrospective study of SDHB and SDHD NIH patients' cohort, which included 41 patients with SDHB mutation-related PHEO/sPGL and 18 patients with either SDHD or SDHB mutation-related head and neck PGL (HNPGL) with both CgA and NMN measured at the time of diagnosis at NIH.
|
24467715 |
2014 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We can conclude that plasma CGA concentration as determined by radioimmunometric assay (which is simple without the necessity of special laboratory equipment) is an effective marker of pheochromocytoma with association to malignity and tumor mass.
|
18271679 |
2008 |
|
Pheochromocytoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we therefore compared tumour and plasma levels of CGA in patients with phaeochromocytoma associated with the two syndromes.
|
18046660 |
2007 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have recently validated several assays for the measurement of peptides derived from chromogranin A (CgA) and secretogranin II (SgII) in order to determine whether these secreted neuroendocrine products could provide useful, complementary markers for the diagnosis and prognosis of PHEOs.
|
17102122 |
2006 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
After excision of benign pheochromocytoma, chromogranin A (P=0.028), norepinephrine (P=0.047), and epinephrine (P=0.037) all fell to values near normal.
|
11116123 |
2000 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also screened members of families with MEN-2 or von Hippel-Lindau disease for pheochromocytoma by measuring plasma and urine catecholamines and plasma chromogranin A and by performing abdominal ultrasonography, CT and MRI, and metaiodobenzylguanidine scintigraphy.
|
8105382 |
1993 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The change in chromogranin A plasma concentration after pheochromocytoma resection best fit a two-compartment model, with an initial rapid half-life time of 16 minutes, followed by a longer half-life time of 520 minutes.
|
2189303 |
1990 |
|
Pheochromocytoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An mRNA of approximately 2.3Kb was detected with the cDNA probes in human cell lines from MTC and lung cancers that were shown to produce CgA and in human pheochromocytoma and bovine adrenal medulla tissue.
|
3718511 |
1986 |
|
Non-Small Cell Lung Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
For neoplastic disease (NSCLC, SCC), CgA was elevated in 11-16%.
|
30995665 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
CYFRA 21.1 (p < 0.001, r = 0.394), HE4 (p = 0.014, r = 0.279) and CgA (p = 0.023, r = 0.259) levels were positively correlated with tumor stage in NSCLC.
|
29729229 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
REST expression was restricted in non-small cell lung cancer (NSCLC) cells, and knockdown of REST could cause as much SYPT expression as in SCLC cells and weak CGA expression in NSCLC cells.
|
22449227 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
|
21595568 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
In the circulation, CGA and Pro-GRP appear to bear important information related to the prognosis for NSCLC patients before chemotherapy.
|
16340245 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
It is concluded that CgA gene expression can be revealed in NSCLC at both mRNA and protein levels and that RT-PCR is a valuable tool for identifying NE differentiated NSCLCs.
|
9924430 |
1998 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
These results suggest that the CHGA gene is associated with the risk of developing schizophrenia in the Japanese population.
|
16504480 |
2006 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the CHGA gene is associated with the risk of developing schizophrenia in the Japanese population.
|
16504480 |
2006 |
|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
LHGDN |
These results suggest that the CHGA gene is associated with the risk of developing schizophrenia in the Japanese population.
|
16504480 |
2006 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
LHGDN |
The results indicate that there may be a decrease in the number of CgA positive large dense-core vesicles per terminal, and/or in the number of CgA positive terminals, suggesting possible functional impairment of prefrontal synaptic contact in schizophrenia.
|
15337252 |
2004 |
|
Hypertensive disease
|
0.300 |
Biomarker
|
group |
BEFREE |
In rodents, the administration of catestatin decreases hypertension, cardiac contractility, obesity, atherosclerosis, and inflammation, and it improves insulin sensitivity.
|
31588572 |
2019 |
|
Hypertensive disease
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Consistent with human findings, the lack of CST in CgA knockout (Chga-KO) mice eventuates in the development of hypertension and supplementation of CST to Chga-KO mice restores blood pressure, implicating CST as a key player in regulating hypertension.
|
28443506 |
2018 |